Shield Therapeutics

Results of 2021 Annual General Meeting

RNS Number : 2902C
Shield Therapeutics PLC
17 June 2021
 

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

 

Results of 2021 Annual General Meeting

 

 

London, UK, 17 June 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer® (ferric maltol), announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2021. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below.

 

The following table shows the votes cast on each resolution:

 

 

VOTES FOR

%

VOTES AGAINST

%

VOTES WITHELD

Resolution 1

115,096,905

99.94

6,544

0.01

883,488

Resolution 2

115,083,904

99.2

866,271

0.75

36,762

Resolution 3

115,083,904

99.2

866,271

0.75

36,762

Resolution 4

115,927,366

99.93

25,810

0.02

36,761

Resolution 5

115,086,905

99.2

866,271

0.75

36,761

Resolution 6

115,082,443

99.2

867,732

0.75

36,762

Resolution 7

115,083,904

99.2

866,271

0.75

36,762

Resolution 8

115,114,781

99.2

866,695

0.75

5,461

Resolution 9

115,956,508

99.93

27,207

0.02

3,222

Resolution 10

115,905,527

99.91

47,834

0.04

33,576

Resolution 11

115,719,269

99.75

228,432

0.2

39,236

Resolution 12

114,882,135

99.03

1,065,566

0.92

39,236

 

Notes:

1.  Number of shares in issue 215,837,965.

2.  Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/ .

3.  Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

 

 

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Greg Madison, CEO

+44 (0)19 1511 8500

Lucy Huntington-Bailey (General Counsel and Company Secretary)

 

 

Nominated Adviser and Joint Broker

 

Peel Hunt LLP

 

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

 

 

Joint Broker

finnCap Ltd 

Geoff Nash/Matt Radley/Alice Lane 

 

 

+44 (0)20 7220 0500

 

 

 

Financial PR & IR Advisor

 

Walbrook PR

+44 (0)20 7933 8780 or  shie[email protected]

Paul McManus/Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303

 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGMZGMVFNLGMZM